WallStSmart

Vale SA ADR (VALE)vsVersamet Royalties Corporation Common Stock (VMET)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Vale SA ADR generates 293861% more annual revenue ($218.07B vs $74.18M). VMET leads profitability with a 49.9% profit margin vs 4.8%. VMET trades at a lower P/E of 26.4x. VMET earns a higher WallStSmart Score of 60/100 (C+).

VALE

Buy

57

out of 100

Grade: C

Growth: 3.3Profit: 5.5Value: 8.7Quality: 5.0
Piotroski: 2/9Altman Z: 1.13

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.0Value: 5.3Quality: 4.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

VALEUndervalued (+76.7%)

Margin of Safety

+76.7%

Fair Value

$74.64

Current Price

$13.82

$60.82 discount

UndervaluedFair: $74.64Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VALE5 strengths · Avg: 8.6/10
PEG RatioValuation
0.3110/10

Growing faster than its price suggests

Market CapQuality
$61.58B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.0%8/10

Strong operational efficiency at 22.0%

Free Cash FlowQuality
$1.24B8/10

Generating 1.2B in free cash flow

VMET5 strengths · Avg: 9.6/10
Profit MarginProfitability
49.9%10/10

Keeps 50 of every $100 in revenue as profit

Operating MarginProfitability
58.0%10/10

Strong operational efficiency at 58.0%

Revenue GrowthGrowth
391.9%10/10

Revenue surging 391.9% year-over-year

EPS GrowthGrowth
2123.0%10/10

Earnings expanding 2123.0% YoY

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

VALE4 concerns · Avg: 3.3/10
P/E RatioValuation
28.4x4/10

Moderate valuation

Return on EquityProfitability
5.3%3/10

ROE of 5.3% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
26.4x4/10

Moderate valuation

Market CapQuality
$1.03B3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : VALE

The strongest argument for VALE centers on PEG Ratio, Market Cap, Price/Book. PEG of 0.31 suggests the stock is reasonably priced for its growth.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 49.9% and operating margin at 58.0%. Revenue growth of 391.9% demonstrates continued momentum.

Bear Case : VALE

The primary concerns for VALE are P/E Ratio, Return on Equity, Profit Margin. Thin 4.8% margins leave little buffer for downturns.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VALE profiles as a value stock while VMET is a growth play — different risk/reward profiles.

VMET is growing revenue faster at 391.9% — sustainability is the question.

VALE generates stronger free cash flow (1.2B), providing more financial flexibility.

Monitor OTHER INDUSTRIAL METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VMET scores higher overall (60/100 vs 57/100), backed by strong 49.9% margins and 391.9% revenue growth. VALE offers better value entry with a 76.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Vale SA ADR

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

Vale SA produces and sells iron ore and iron ore pellets for use as raw material in steelmaking in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?